Keefe, Bruyette & Woods Downgrades Invesco to Market Perform, Lowers Price Target to $17
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2024
0mins
Source: Benzinga
Get Free Real-Time Notifications for Any Stock
Monitor tickers like IVZ with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on IVZ
Wall Street analysts forecast IVZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVZ is 28.68 USD with a low forecast of 25.00 USD and a high forecast of 33.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
4 Buy
7 Hold
0 Sell
Moderate Buy
Current: 27.560
Low
25.00
Averages
28.68
High
33.50
Current: 27.560
Low
25.00
Averages
28.68
High
33.50
About IVZ
Invesco Ltd. is an independent investment management firm. It serves the retail and institutional markets within the investment management industry in the Americas, Europe, Middle East, and Africa and Asia-Pacific in 120 countries. It offers a range of investment strategies across asset classes, investment styles, and geographies. Its asset classes include equity, fixed income, balanced, alternatives and money market. Its retail assets under management include exchange-traded funds, separately managed accounts, individual savings accounts, investment companies with variable capital, investment trusts, open-end mutual funds, unit investment trusts, and variable insurance funds. Its institutional assets include institutional separate accounts, private funds, open-end mutual funds, and collective trust funds. Its client base includes public and private entities, unions, non-profit organizations, endowments, foundations, financial institutions, and sovereign wealth funds.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Invesco Reports Q4 Earnings Beat with Strong Revenues
- Earnings Beat: Invesco reported Q4 earnings that exceeded market expectations, showcasing the company's resilience and profitability amid market fluctuations.
- Analyst Rating Maintained: Analyst Alexander Blostein reiterated a Neutral rating for Invesco with a price target of $28.75, reflecting a cautiously optimistic outlook on the company's future performance.
- Revenue Growth Driver: The company achieved strong revenue growth in Q4, indicating sustained demand for its investment management services, which may support future performance.
- Positive Market Reaction: Despite the neutral rating from analysts, the market reacted positively to Invesco's earnings, potentially boosting investor confidence and driving stock price increases.
Continue Reading
Invesco Reports Fourth Quarter Earnings Beat
- Earnings Beat: Invesco reported adjusted earnings of 62 cents per share for Q4, exceeding the consensus estimate of 58 cents, indicating strong revenue growth and effective expense management that boosts investor confidence.
- Revenue and Margin Growth: The company posted better-than-expected net management fees and performance fees, with an operating margin of 36.4%, surpassing consensus by over 100 basis points, reflecting ongoing improvements in profitability.
- Analyst Rating: Goldman Sachs analyst Alexander Blostein reiterated a Neutral rating on Invesco with a price target of $28.75, indicating a cautiously optimistic outlook on the company's future performance.
- Future Outlook: While management did not provide specific guidance for 2026, they indicated an increase in Alpha Next gen-related expenses, which analysts believe will not significantly alter the upside potential for IVZ's operating margins.
Continue Reading